deucravacitinib,vedolizumab,zasocitinib,apremilast
takeda,bms,amgen
['psoriasis', 'takeda']
aad 2023: s tak-297 hits endpoints in phase iib psoriasis trial #biotech #pharma #aad2023
Biopharma’s trusted news source. Lynn Yoffee, Jennifer Boggs, Karen Carey, Anette Breindl, Lee Landenberger, Randy Osborne, Mari Serebrov, Caroline Richards